GovChime
Notice ID: d8cb9ce093654279995607bca4a4b9ebSources SoughtArchived

Assessment of Host-targeted Nanobody Therapeutics

Archived on February 5, 2026. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
10:00 AM EST
Posted
January 12, 2026
Notice type
Sources Sought
Set-aside
No Set aside used
NAICS
541715: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Agency
Department of WarDEFENSE HEALTH AGENCY (DHA)

Notice details

Office
DEFENSE HEALTH AGENCY
Place of performance
Frederick, Maryland, 21701
Last updated
Nov 4, 2026
First published
Last updated on SAM.gov

Identifiers

Solicitation number
HT942626QE003
Notice ID
d8cb9ce093654279995607bca4a4b9eb

Description

 Request for Information (RFI)

Title:  Assessment of Host-targeted Nanobody (USAMRIID)

Notice Type: Request for Information (RFI)

Response Date:  21 January 2026

Requiring Activity/Agency Name:  U.S. Army Medical Research of Infectious Diseases (USAMRIID) and all other Defense Health Agency (DHA) labs

RFI INSTRUCTIONS:

Interested parties are asked to respond to this RFI and submit a capabilities statement that supports the focus of this RFI.  Please review the place of performance requirements. Please submit written responses via email in Microsoft Office 2000 or 2007 format.  All responses should be complete: in 12-point font; and not to exceed 3 pages total, including graphics, tables, and appendices.

No hard copies shall be accepted. No written solicitation document is available at this time. Telephone requests will not be honored, and no bidders list shall be maintained. No inquiries regarding any potential future acquisition activities shall be entertained.

Potential offerors are requested to direct all questions via email to the Point of Contact listed below. Responses are due to the Point of Contact, Mr. Grant A. Gratton at email:  grant.a.gratton.civ@health.mil or Emily O’Hara   emily.k.ohara.civ@health.mil no later than 10:00AM ET, Wednesday, 21 January 2026.[EC1] 

DISCLAIMER:  This RFI is issued solely for information and planning purposes and does not constitute a solicitation. Neither unsolicited proposals nor any kinds of offers will be considered in response to this RFI. Responses to this notice are not offers and will not be accepted by the Government to form a binding contract. Responders are solely responsible for all expenses associated with responding to this RFI. All information received in response to this RFI that is marked proprietary will be handled accordingly. Responses to the RFI will not be returned.

 All information received in response to this RFI will be treated as business confidential information. Submitters should properly mark their responses if the information is confidential. All information received in response to this RFI that is marked Proprietary will be handled accordingly.

1.  PURPOSE

The Contractor shall provide all personnel, equipment, supplies, facilities, transportation, tools, materials, supervision, and other items and non-personal services necessary to evaluate host-targeted nanobody therapeutics using established in vitro porcine blood brain barrier (BBB) models and to develop novel in vitro BBB models useful for further characterization of nanobody therapies as defined in this Statement of Objectives (SOO) except for those items specified as government furnished property and services.  The Contractor shall perform to the standards in this contract.

2.  BACKGROUND

USAMRIID works closely with other U.S. Army Medical Research and Development Command (USAMRDC) organizations, Department of War (DoW), the Interagency (including Interagency Laboratories), and private companies to accomplish its mission of protecting the Warfighter from biological threats and being prepared to investigate disease outbreaks or threats to public health.

Defense Health Agency Contracting Activity (DHACA)  and USAMRIID shall issue task orders against this proposed Indefinite Delivery/Indefinite Quantity (IDIQ). Each task order will define the deliverables for each task.  Each task order shall represent a Firm-Fixed-Price response to a DHACA issued Assessment of Host-targeted Nanobody Therapeutic request to evaluate host-targeting nanobody therapies for their ability to bind to and traffic across in vitro BBB models, and potentially other tissue model systems, and shall represent all personnel and materials required to provide a turnkey solution to the Government’s requirement as defined in the SOO.

Numerous neurotropic viral families are considered high priority pathogens to the DoW, but therapeutic development is stymied by the difficulty of trafficking into the Central Nervous System (CNS). This is mediated primarily by BBB tight junctions that prevent large molecule entry into the parenchymal space. However, the CNS has significant physiological needs in the form of energy, oxygen and other molecular components. BBB transporters, receptors and ion channels regulate this via either non-specific transcytosis, specific carrier-mediated transport (CMT) or receptor-mediated transcytosis (RMT). As part of a Defense Threat Reduction Agency (DTRA) funded effort to address these challenges, we will target various transporters expressed on the luminal side of the BBB with host-targeting nanobodies to transport molecules on a blood-to-brain directional gradient for therapeutic payload delivery. To provide multiple shots on goal, we aim to develop nanobodies against a diverse set of BBB transporters with a range of species-specificities to identify the optimal targeting strategy in the context of neurotropic viral infections. Via this IDIQ, we will contract out the in vitro BBB modeling assessment of host-targeting nanobodies and refinement of in vitro and in vivo evaluation systems that will be leveraged in outyears to down-select optimal host-targeting nanobody candidates for continued development.

3. SCOPE OF EFFORT

The Government intends to award an IDIQ contract for the assessment of host-targeting nanobody therapies (to be provided to the performer by USAMRIID) using in vitro BBB models. These services include but are not limited to the characterization of porcine BBB arenavirus infection models, determining the mechanism of nanobody transmigration across the BBB, and establishment and characterization of a marmoset BBB model. Each task order is unique in scope and will require flexibility in design, schedule, and execution, details of which will be specified for each task order.

  • The Contractor shall refine in vitro BBB models for the assessment of nanobody therapeutic transmigration in the context of viral infection. The Contractor, as subject matter experts on the in vitro BBB model and virologic assessment, shall utilize applicable technical methods to assess in vitro BBB models following infection with a pathogen of interest to characterize BBB targets for prioritization. Contractor shall deliver a comprehensive report detailing the technical methods used and the targets identified.

  • The Contractor shall utilize applicable technical methods to establish baseline transmigration efficiencies for non-targeted nanobody therapies. Contractor shall deliver a comprehensive report establishing baseline transmigration efficiencies, detailing the methods, data, and analysis used.

  • The Contractor shall utilize applicable technical methods to assess transmigration efficiencies for BBB-targeted nanobody therapies. Contractor shall deliver a comprehensive report assessing transmigration efficiencies, detailing the methods, data, and analysis used.

  • The Contractor shall utilize applicable technical methods to establish a BBB model of NHP origin, providing a species-relevant model for human BBB-targeted nanobody therapy assessment. Contractor shall deliver a validated BBB model and a detailed characterization report. Validation criteria must be pre-approved by the  Technical Representative.

  • The Contractor shall work with USAMRIID to provide subject-matter expertise on in vitro BBB models and advise on optimal targets for BBB targeting nanobody therapeutics. Contractor shall provide documented subject-matter expertise and guidance, demonstrated through meeting minutes, reports, and other documentation.

4. PLACE AND PERIOD OF PERFORMANCE (POP)

The contract shall be an IDIQ contract with a five-year ordering period for novel large surface area microparticle drug products suitable for treatment in animal models of infectious disease. A six month FAR 52.217-8 Option Period, if required, will be exercised. The place of performance will be at the contractor’s facility.

5. Administrative Tasks

The Contractor shall provide study protocol and budget; integrated master schedule; market sustainment plan; monthly IPT meetings; quarterly task status reports that describe the progress made within the period and costs incurred; spend plan; and documents inclusive of a final study report.  Each of these items must be addressed in the Offeror’s SOW.

The Government will utilize a Quality Assurance Surveillance Plan (QASP) that serves to monitor performance and to ensure that the Government is receiving the services specified in the contract and that the services meet the performance standards specified in the contract. By employing a fully developed QASP, the Government and the Contractor achieve an understanding of performance expectations and how performance will be measured against those expectations.  The QASP may be negotiated between the Government and the contractor prior to final contract award. 

USE OF TECHNICAL REFERENCE FACILITY

To the extent practical the Contractor shall utilize the technical reference facilities of the Defense Technical Information Center (DTIC) for the purpose of surveying existing knowledge and avoiding needless duplication of scientific and engineering effort and the expenditure thereby represented. The DTIC headquarters office is located at 8725 John J. Kingman Road, Fort Belvoir, VA 22060-6218. Information can also be obtained via the Internet at http://www.dtic.mil or via the toll-free number for the DTIC help desk, 1-800-225-3842. To the extent practical, all other sources, whether Government controlled, should be consulted for the same purpose.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Contracting Officer

Primary Contact

Secondary Contact

Documents

Files (1)

  • A02-SOO 12-31-2025.docx

    26 KBAdded in Sources Sought version 1Posted
    Download

Lifecycle

  1. 1
    Version 1Sources SoughtArchived

    Assessment of Host-targeted Nanobody Therapeutics

    Notice 37a309976cd744b89e169bddc7ba06fb on SAM.gov

  2. 3
    Version 3Sources SoughtArchivedCurrent

    Assessment of Host-targeted Nanobody Therapeutics

    Notice d8cb9ce093654279995607bca4a4b9eb on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
UPDATE #1 – Amendment #0001 to the RFP was released on October 22, 2026. UPDATE #2 – Amendment #0002 to the RFP was released on October 26, 2026. The National Aeronautics and Space Administration (NASA), Goddard Space Flight Center (GSFC), hereby invites interested parties to review the Final Request for Proposal (FRFP) for the Hydrosphere, Biosphere, and Geophysics (HBG) Support Services II requirement supporting the Earth Sciences Division (ESD) at NASA/GSFC. The principal purpose of this requirement is to provide science research that conceives, develops, and applies space, field-deployed (i.e. airborne and in situ) and laboratory based technologies and observations to address issues of importance to society. These include but are not limited to water resources, land and ocean ecosystems, global and regional sea level change, changes in the Earth’s cryosphere, gravity field, magnetic field, solid Earth, and the terrestrial reference frame. The Statement of Work, Attachment A, describes the scope of the requirement. This contract is for support of a full range of science and research activities across the breadth of the various Laboratories that make up the HBG sub-division: the Cryospheric Sciences, Ocean Ecology, Hydrological Sciences, Biospheric Sciences, and Geodesy and Geophysics Laboratories. This contract is also for support of science, research and computing activities within the Terrestrial Information Systems Laboratory (TISL), also in the ESD. For the purposes of this document and contract the term HBG will be used to encompass all the Laboratories of the HBG sub-division and the TISL. NASA will conduct this acquisition as a small business set-aside. This competitive acquisition was originally contemplated as a Cost-Plus-Fixed-Fee (CPFF), Indefinite-Delivery/Indefinite-Quantity (IDIQ) contract with the ability to issue CPFF task orders. Following further acquisition planning and assessment of the Government's requirements, the contract structure has been modified. The HBG II Draft Request for Proposal (DRFP) posted on April 8, 2025 was issued as an IDIQ CPFF solicitation. As amended, this competitive acquisition will now result in a HYBRID Indefinite Delivery Indefinite Quantity (IDIQ) with the ability to issue Cost Plus Fixed Fee (CPFF) AND Firm- Fixed Price (FFP) task orders. The contract will have an effective ordering period of five years from the contract effective date. Interested offerors are encouraged to review the solicitation and all associated attachments for complete details regarding the requirements and proposal submission instructions. Please see the attached cover letter for additional information.
64%
Solicitation12/04/2026
SEE AMENDMENT 0009 for updated Attachment 01. All changes are highlighted in Yellow.
64%
Special Notice10/31/2027
SEE AMENDMENT 08. Changes are highlighted in yellow. *NOTE: Requests for viewing CUI documents must be accompanied by the Contractor's JCP Certification Number and CAGE Code. If you DO NOT include the required information, your request will be DENIED. If your request is denied, you will need to re-request with your JCP Certification Number and CAGE
64%
Special Notice10/31/2027
06 August 2024: See updated CUI 01 Attachment Research Topics REV 004 ____________________________________________________________________________________ 10 June 2024: See highlighted changes on page 14 of this document and reference attachment 01_AMD 003 _____________________________________________________________________________ 28 February 2024: Revision 5: See highlighted changes on page 16 of this document only. _______________________________________________________________________________________________ 18 January 2024: See BAA Revision 004. Changes highlighted in yellow Significant update made to CUI Attachment 01, REVISION 002: Some topics are removed from ther BAA (see strikethrough), new topics are added (see hellow highlights) ________________________________________________________________________________________________ 16 November 2023: See BAA Revision 003. Changes highlighted in yellow. Significant update made to CUI Attachment 01, REVISION 001: Some topics are removed from ther BAA (see strikethrough), new topics are added (see hellow highlights) ****************************************************************************************************************************************************** See AMENDMENT 0002 published 14 Devcember 2022. CHanges are highlighted in yellow. PAGE 3 "The Command, Control, Communications, Computers, Cyber, Intelligence, Surveillance, and Reconnaissance (C5ISR) Center is an element of the U.S. Army Combat Capabilities Development Command (DEVCOM). Through collaboration across the command’s core technical competencies, DEVCOM leads in the discovery, development and delivery of the technology-based capabilities required to make Soldiers more lethal to win our nation’s wars and come home safely. DEVCOM is a major subordinate command of the U.S. Army Futures Command (AFC)." PAGER 11 "All submissions, technical questions, or topic clarifications shall be submitted via the ESI BAA Acquisition Mailbox- usarmy.apg.devcom-c5isr.mbx.esi-bus-ops-acq-baa@army.mil. The subject line of the email should reference the BAA Number. No discussions by the technical staff are to be held with Offeror after proposal submission without PRIOR authorization from the Contracting Officer/Agreements Officer. ESI BAA Mailbox usarmy.apg.devcom-c5isr.mbx.esi-bus-ops-acq-baa@army.mil" PAGE 12 "To request access to download the controlled attachment, click on the tab for “Attachment/Links, then click on the title of the controlled document. When you receive the pop-up window to request access, enter the reason for the request in the window, making sure to include your entity’s CAGE Code and JCP Certification Number then hit submit. Once the notice is submitted, the access status on the controlled document will change to “Pending”. The Access POC will review your request, granting access if requirements are met or reject for correction." See AMENDMENT 0001 published 9 November 2022. Changes are highlighted in yellow. Requests for viewing CUI documents must be accompanied by the Contractor's JCP Certification Number and Cage Code. If your request is denied, you will need to re-request with your JCP Certification Number and Cade Code. Nothing else in the original announcement has changed.
64%
Special Notice10/31/2027
The mission of ESI Directorate is to provide support for rapidly integrating and maturing ESI technologies onto ground and air platforms and for rapid prototyping to define, ideate, and test, to “learn by doing” and enable Solider-centric System Design. ESI explores how to manage and securely transmit trustworthy data as it transverses the Army’s network. This BAA invites industry to submit innovative proposals that address the technical portfolio areas of the ESI Directorate: Systems Integration (SI), C5I Engineering and Readiness Engineering.
64%
Pre-Solicitation10/31/2027

Additional Details

Solicitation Number

HT942626QE003

Archive Date

Feb 5, 2026

Office Address

FORT DETRICK, MD, 21702